XML 47 R39.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Summary of Operating Costs and Expenses and Interest Expense, Net |
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Product Revenue, net |  | $ | 390 |  |  | $ | — |  |  | $ | 390 |  |  | $ | — |
Segment cost of sales |  |  | (20 | ) |  |  | — |  |  |  | (20 | ) |  |  | — |
Amortization of intangible asset (a) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Segment research and development (b) (c) |  |  | (1,244 | ) |  |  | (3,077 | ) |  |  | (2,795 | ) |  |  | (8,998 | )
Segment selling, general and administration (b) (c) |  |  | (6,449 | ) |  |  | (1,734 | ) |  |  | (13,320 | ) |  |  | (5,731 | )
Share-based compensation expense (see Note 15) |  |  | (53 | ) |  |  | (68 | ) |  |  | (170 | ) |  |  | (274 | )
Depreciation and amortization |  |  | (355 | ) |  |  | (8 | ) |  |  | (1,055 | ) |  |  | (23 | )
Operating loss |  | $ | (7,731 | ) |  | $ | (4,887 | ) |  | $ | (16,970 | ) |  | $ | (15,026 | )
a) Amortization expense of $349 and $1,036 related to the Pfizer Intangible Asset has been excluded for the three and nine months ended September 30, 2025, respectively, and included within depreciation and amortization. b) Share-based payment expense of $15 and $50 related to research and development and $38 and $120 related to general and administration have been excluded for the three and nine months ended September 30, 2025, respectively, and included within share-based compensation expense. Share-based payment expense of $25 and $147 related to research and development and $43 and $127 related to general and administration have been excluded for the three and nine months ended September 30, 2024, respectively, and included within share-based compensation expense. c) Depreciation expense of $2 and $7 related to research and development and $4 and $12 related to general and administration have been excluded for the three and nine months ended September 30, 2025, respectively, and included within depreciation and amortization. Depreciation expense of $5 and $14 related to research and development and $3 and $9 related to general and administration have been excluded for the three and nine months ended September 30, 2024, respectively, and included within depreciation and amortization. Interest Expense, Net
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Interest income |  | $ | 121 |  |  | $ | 166 |  |  | $ | 406 |  |  | $ | 607 |
Interest expense |  |  | (562 | ) |  |  | (756 | ) |  |  | (1,697 | ) |  |  | (2,255 | )
Interest expense, net |  | $ | (441 | ) |  | $ | (590 | ) |  | $ | (1,291 | ) |  | $ | (1,648 | )
Schedule of Distribution of Long-Lived Assets by Geographical Area | The distribution of long-lived assets by geographical area was as follows:
Long-lived assets |  | September 30, 2025 |  |  | December 31, 2024 |
Ireland |  | $ | 18,736 |  |  | $ | 19,759 |
U.S. |  |  | 11 |  |  |  | 15 |
Total |  | $ | 18,747 |  |  | $ | 19,774 |

X
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration